Yoon EL, Yuk JS., et al. - A retrospective cohort study was performed to ascertain the incidence of liver disease with ulipristal acetate (UPA) vs gonadotropin-releasing hormone (GnRH) agonists. In this study, 17,207 patients were treated with GnRH agonists and 20,926 patients with UPA among patients with uterine fibroids. There were 11,445 individuals after 1:1 propensity score matching for each group. The results of this study demonstrated that the incidences of severe liver disease, hepatic failure, and toxic liver disease did not differ between the UPA and GnRH agonist groups. Nevertheless, the study found a higher incidence of mild liver disease in the UPA group vs the GnRH agonist group. With UPA, the incidence of hepatic damage was very low.